Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Nov;17(11):1063-6.

Investigation of pregnancy outcome and ovarian hyper stimulation syndrome prevention in agonist and antagonist gonadotropin-releasing hormone protocol

Behnaz Khani Rabati  1 , Setare Nasiri Zeidi
Affiliations

Investigation of pregnancy outcome and ovarian hyper stimulation syndrome prevention in agonist and antagonist gonadotropin-releasing hormone protocol

Behnaz Khani Rabati et al. J Res Med Sci. 2012 Nov.

Abstract

Background: Given the controversies regarding the effectiveness of gonadotropin-releasing hormone (GnRH) antagonists in prevention of ovarian hyper stimulation syndrome stimulation, this study was designed to compare GnRH agonist protocol with GnRH antagonist protocol in patients who were candidate for assisted reproductive techniques (ARTs).

Materials and methods: This investigation was performed on 136 patients who were randomly allocated to two groups of GnRH agonist and GnRH antagonist. In the first group stimulation was performed by administration of Buserelin, and in the second group, it was performed by giving Cetrorelix. Then patients were compared regarding results of ovarian stimulation, pregnancy outcomes and rate of ovarian hyper stimulation syndrome (OHSS).

Results: There were not significant differences between 2 groups regarding the ovarian stimulation, pregnancy outcomes and rate of OHSS (P value >0.05).

Conclusion: Administration of GnRH antagonists in ovarian stimulation will be a reasonable option to GnRH agonists in assessment reproduction treatment; however, further studies are suggested.

Keywords: Assisted reproductive techniques; gonadotropin-releasing hormone agonist; gonadotropin-releasing hormone antagonist; ovarian hyper stimulation syndrome; ovarian stimulation; pregnancy rate.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. Macklon NS, Stouffer RL, Giudice LC, Fauser BC. The science behind 25 years of ovarian stimulation for in vitro fertilization. Endocr Rev. 2006;27:170–207. - PubMed
    1. Santos MA, Kuijk EW, Macklon NS. The impact of ovarian stimulation for IVF on the developing embryo. Reproduction. 2010;139:23–34. - PubMed
    1. Al-Inany H, Wahba A, Peitsidis P. Changing attitudes in ovarian stimulation. Womens Health (Lond Engl) 2011;7:505–7. - PubMed
    1. European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod. 2001;16:644–51. - PubMed
    1. Felberbaum RE, Reissmann T, Küpker W, Bauer O, al Hasani S, Diedrich C, et al. Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (Cetrorelix) in women with tubal infertility. Eur J Obstet Gynecol Reprod Biol. 1995;61:151–5. - PubMed

LinkOut - more resources